Development of Practical Artificial Intelligence System for Drug Discovery and Its Application to Activity Prediction of Small Molecule Protein-Protein Interaction Modulators

Hirotsugu Komatsu,Ken Ikeda,Takeshi Tanaka,Takao Matsuzaki
DOI: https://doi.org/10.14533/jbm.19.5
2019-01-01
Journal of Biological Macromolecules
Abstract:Degree of attention to protein-protein interaction (PPI) are increasing under circumstances ofthe exhaustion of conventional drug targets such as enzymes, receptors and channels whose ligandsare non-protein. However, identification of potent small molecule PPI modulators are stillchallenging for pharmaceutical industries because in-house chemical libraries of pharmaceuticalcompanies do not include strong and specific binders to PPI targets, and it is difficult to identifyactive compounds by high-throughput screening (HTS). On the other hand, to improve lowproductivity of drug research and developments (R&D), which is one of the most important longstanding issues for pharmaceutical industries, application of artificial intelligence (AI) to manystages of drug R&D is being tried by large number of pharmaceutical companies, academicinstitutions and biotech companies. However, a part of researchers of pharmaceutical companiesalso have opinions with a skeptic tone for the contribution of AI to the improvement of lowproductivity of drug R&D. Based on these situations, we review current approaches of applicationof AI to drug discovery researches and introduce Interprotein’s approach to identify potent smallmolecule PPI modulators with an AI-based activity prediction system.
What problem does this paper attempt to address?